<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294942</url>
  </required_header>
  <id_info>
    <org_study_id>TSHRN1201</org_study_id>
    <nct_id>NCT02294942</nct_id>
  </id_info>
  <brief_title>Extended-Release RANCAD in the Patients With Stable Angina Pectoris</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Effects of add-on RANCAD on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TSH Biopharm Corporation Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of&#xD;
      add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina&#xD;
      pectoris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test&#xD;
      (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ETT performing at last treatment visit (Week 12).</measure>
    <time_frame>Week 12 (not including screening &amp; follow-up period)</time_frame>
    <description>To compare the change from baseline of ETT performing duration between add-on RANCAD and placebo at trough (12 hours after dosing) at Week 12.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Stable Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>RANCAD 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RANCAD 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RANCAD 2 tabs (500 mg), twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tabs, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RANCAD</intervention_name>
    <description>Extended-Release RANCAD</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RANCAD 1000mg</arm_group_label>
    <arm_group_label>RANCAD 500mg</arm_group_label>
    <other_name>RNTA06</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged ≥ 20 years old&#xD;
&#xD;
          2. A minimum 3-month history of stable angina&#xD;
&#xD;
          3. Patients with diagnosis of coronary artery disease (CAD)&#xD;
&#xD;
          4. Patients present with the symptoms of stable angina after withdrawn from other&#xD;
             antianginal drugs and given the required background therapy for at least 7 days will&#xD;
             be qualified for entering this study and performing 1st ETT qualifying test&#xD;
&#xD;
          5. Patients developed exercise-induced ECG ischemiai during two qualifying exercise&#xD;
             treadmill testsii. The difference between twoiii tests should be ≤ 20% of the longer&#xD;
             test or ≤ 1 minute i. Exercise-induced ECG ischemia is defined as the new development&#xD;
             of horizontal or down-sloping ST-segment depression of ≥1mm at 60-80ms after the J&#xD;
             point; if patients with baseline ST depression at rest (&lt;1mm), qualifying ST segment&#xD;
             depression is defined as additional ST depression of at least 1 mm below the resting&#xD;
             value ii. Exercise treadmill test (ETT) will be performed by Modified Bruce Protocol.&#xD;
             iii. Two qualifying tests will be conducted 1 week apart, a 3rd ETT test will be&#xD;
             performed ≤ 3 days when differences between previous two qualifying ETTs &gt;20% of the&#xD;
             longer test or &gt;1 minute&#xD;
&#xD;
          6. Willing and able to provide a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Factors that might compromise ECG or ETT interpretation&#xD;
&#xD;
               -  Patients with resting ST-segment depression ≥ 1mm in any lead&#xD;
&#xD;
               -  Left bundle-branch block&#xD;
&#xD;
               -  Patients implanted with pacemaker&#xD;
&#xD;
               -  Patients under Digitalis therapy&#xD;
&#xD;
          2. Patients with family history of (or congenital) long QT syndrome&#xD;
&#xD;
          3. Patients with congenital heart disease&#xD;
&#xD;
          4. Patients with uncorrected valvular heart disease&#xD;
&#xD;
          5. Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2&#xD;
             months prior enter this study&#xD;
&#xD;
          6. Female who is pregnant/lactating or planning to be pregnant, or female of childbearing&#xD;
             potential* who is not using medically recognized method of contraception&#xD;
&#xD;
             *Other than those who have been surgically sterilized (defined as having undergone&#xD;
             hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation&#xD;
             alone is not considered sufficient) or one year post-menopausal.&#xD;
&#xD;
          7. Patients are under any one of the following conditions:&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class III or Class IV congestive heart failure&#xD;
                  (CHF)&#xD;
&#xD;
               -  QTc &gt; 450 msec at screening&#xD;
&#xD;
               -  Active myocarditis, pericarditis, hypertrophic cardiomyopathy&#xD;
&#xD;
               -  Uncontrolled hypertension (defined as SBP &gt; 180 mmHg) Voltage criteria for left&#xD;
                  ventricular hypertrophy in the absence of repolarization abnormalities will not&#xD;
                  be exclusion criteria&#xD;
&#xD;
          8. Use of any investigational product ≤ 4 weeks prior to screening&#xD;
&#xD;
          9. Patients with severe hepatic disease (e.g., liver cirrhosis)&#xD;
&#xD;
         10. Patients with impaired renal function (defined as serum Cr &gt;1.5 mg/dl)&#xD;
&#xD;
         11. Patients with any condition or disease which is considered not suitable for this study&#xD;
             by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juey-Jen Hwang, M.D., Ph.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei city</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong WuHoSu Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNTA06</keyword>
  <keyword>RANCAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

